This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Esperion Therapeutics, Inc.
Drug Names(s): ETC1002, bempedoic acid
Description: ETC-1002 is an oral small molecule that inhibits fatty acid and cholesterol synthesis, and also enhances oxidation of fatty acids. It is believed to work by inhibiting ATP citrate lyase (ACL)--which is part of the cholesterol-synthesis pathway, a couple of steps upstream from the enzyme inhibited by statins--and interacting with acyl-CoA synthase to increase the AMP/ATP ratio, which the company believes activates AMP-kinase. The company believes the drug also directly activates AMP-kinase, though the precise mechanism is unclear.
Deal Structure: In December 2003, Esperion was acquired by Pfizer. In May 2008, Pfizer sold Esperion to an entity funded by a syndicate of investors. Pfizer has an equity stake in the new Esperion.
Additional information available to subscribers only: